Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-06-22T08:28:32.615Z Has data issue: false hasContentIssue false
  • English
  • Français

Double-Blind Cross-Over Placebo Controlled Study of Flunarizine in Patients With Therapy Resistant Epilepsy

Published online by Cambridge University Press:  18 September 2015

E. Starreveld ,
F. de Beukelaar ,
A.F. Wilson ,
D.R. McLean  and
Helen P. Findlay
E. Starreveld*
Affiliation:
Adult Convulsive Disorder Clinic, Glenrose Rehabilitation Hospital, Edmonton
F. de Beukelaar
Affiliation:
Janssen Research Foundation, Beerse, Belgium
A.F. Wilson
Affiliation:
Adult Convulsive Disorder Clinic, Glenrose Rehabilitation Hospital, Edmonton
D.R. McLean
Affiliation:
Adult Convulsive Disorder Clinic, Glenrose Rehabilitation Hospital, Edmonton
Helen P. Findlay
Affiliation:
Janssen Research Foundation, Beerse, Belgium
*
Adult Convulsive Disorder Clinic, Glenrose Rehabilitation Hospital, 10230 - 111 Avenue, Edmonton, Alberta, Canada T5G 0B7
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Twenty-five patients with long-standing therapy resistant epilepsy were studied in an eight-month double- blind cross-over add-on trial with a daily dose of 15 mg flunarizine. In five patients the seizure frequency decreased 50% or more. The mean seizure frequency reduction in the patients on flunarizine was 35%. Particularly the control of secondary generalized seizures improved. Flunarizine did not significantly alter the plasma levels of the regular anticonvulsant drugs. Minimal adverse side effects were reported equally in the flunarizine and the placebo group. In three patients depressive symptoms improved and two patients became free of postictal headaches. Flunarizine appears to be a safe adjuvant anticonvulsant.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 16 , Issue 2 , May 1989 , pp. 187 - 190
Copyright
Copyright © Canadian Neurological Sciences Federation 1989

References

REFERENCES

1.Michiels, M, Hendriks, A, Knaeps, F, et al. Absorption and tissue distribution of flunarizine in rats, pigs and dogs. Arzneimittel-Forsch 1983; 33: 1135–1142.Google ScholarPubMed
2.Desmedt, CKC, Niemegeers, CJE, Janssen, PAJ, Anticonvulsant properties of cinnarizine and flunarizine in rats and mice. Arzneimittel-Forsch 1975; 25: 1408–1413.Google ScholarPubMed
3.Ashton, D, Wauquier, A, Behavioral analysis of the effects of 15 anticonvulsants in the amygdaloid kindled rat. Psychopharm (Berlin) 1979a; 65: 7–13.CrossRefGoogle ScholarPubMed
4.Wauquier, A, Ashton, D, Melis, W, Behavioral analysis of amygdaloid kindling in beagle dogs and the effects of clonazepam, diazepam, phenobarbital, diphenylhydantoin and flunarizine on the seizure manifestation. Exp Neurol 1979; 64: 579–586.CrossRefGoogle ScholarPubMed
5.Ashton, D, Wauquier, A, Effects of some antiepileptic, neuroleptic and gabaminergic drugs on convulsions induced in rats by injection of D,L-allylglycine. Pharm Biochem Behav 1979b; 11: 221–226.CrossRefGoogle ScholarPubMed
6.Ashton, D, Marrannes, R, Pauwels, PJ, et al. Possible mechanisms of flunarizine's anticonvulsant activity. Photosensitizers. In: Vanden Bussche, G, Wauquier, A, Schmidt, D, Meinardi, H, eds. Proc. Int. Workshop on Flunarizine in Epilepsy: Health Science Review. 1985; 45–59.Google Scholar
7.Meldrum, B, Griffiths, T, Evans, M. Hypoxia and neuronal hyperexcitability:a clue to mechanisms of brain protection. In: Wauquier, A, Borgers, M, Amery, WK, eds. Protection of Tissue Against Hypoxia: Amsterdam: Elsevier Biomedical Press 1982; 276.Google Scholar
8.Amery, WK, Wauquier, A, Van Nueten, JM, et al. The antimigrainous pharmacology of flunarizine (R 14950), a calcium-antagonist. Drugs Exp Clin Res 1981; 7: 1–10.Google Scholar
9.Van Nueten, JM, Van Beek, J, Janssen, PAJ, Effect of flunarizine on calcium-induced responses of peripheral vascular smooth muscle. Arch Int Pharmacodyn Ther 1978; 232: 42–52.Google ScholarPubMed
10.Van Nueten, JM, Vanhoutte, PM, Improvement of tissue perfusion with inhibitors of calcium influx. Biochem Pharmacol 1980; 29: 479.CrossRefGoogle Scholar
11.Louis, P. A double-blind placebo controlled prophylactic study of flunarizine(Sibelium) in migraine(Sibelium) in migraine. Headache 1981; 21: 235–239.CrossRefGoogle Scholar
12.Diamond, S, Schenbaum, H. Flunarizine, a calcium channel blocker, in the prophylaxis of migraine. Headache 1983; 23: 39–42.CrossRefGoogle ScholarPubMed
13.Amery, WK, Caeri, LI, Aerts, TJL. Flunarizine, a calcium entry blocker in migraine prophylaxis. Headache 1985; 25: 249–254.CrossRefGoogle ScholarPubMed
14.Domschky, K, Nelson, M, Dammhayn, B, et al. Flunarizine in patients with insufficient cerebral and peripheral blood flow — a multicentre double-blind study. Med West 1977; 28: 1062–1064.Google Scholar
15.Oosterveld, WJ, Flunarizine in vertigo. A double-blind placebo controlled cross-over evaluation of a constant-dose schedule. ORL 1982; 44: 72–80.CrossRefGoogle ScholarPubMed
16.Casaer, P, Azou, M. Flunarizine in alternating hemiplegia in childhood. Lancet 1984; 2: 579.CrossRefGoogle ScholarPubMed
17.Andermann, F, Silver, K, Hilaire, MHS, et al. Paroxysmal alternating hemiplegia of childhood: treatment with flunarizine and other agents. Neurology 1986; 36 (Suppl1): 327.Google Scholar
18.Declerck, AC, Wauquier, A, Double-blind study of the effectiveness of flunarizine in therapy-resistant epilepsy in mentally retarded children [Abstract]. Proceedings of the 11th Epilepsy International Symposium. Vancouver: Epilepsy International 1978; 169.Google Scholar
19.Overweg, J, Binnie, CD, Meijer, JWA, et al. Double-blind placebocontrolled trial of flunarizine as add-on therapy in epilepsy. Epilepsia 1984; 25 2: 217–222.CrossRefGoogle ScholarPubMed
20.Binnie, CD, de Beukelaar, F. Meijer, JWA, et al. Open dose-ranging trial of flunarizine as add-on therapy in epilepsy. Epilepsia 1985; 26 5: 424–428.CrossRefGoogle ScholarPubMed
21.Koch, GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972; 28 577–584.CrossRefGoogle Scholar
22.Overweg, J, Ashton, D, de Beukelaar, F, et al. Add-on therapy in epilepsy with calcium entry blockers. Eur Neurol 1986; 25: (Suppl1): 93–101.CrossRefGoogle ScholarPubMed
23.Chouza, C, Caamaro, JL, Aljanati, R, et al. Parkinsonism, tardive dyskinesia, akathisia and depression induced by flunarizine. Lancet 1986, June 7: 1303–1304.CrossRefGoogle Scholar
24.Heinze, B, Karrass, W, Peters, Th. Pharmacopsychological effects of flunarizine in geriatric patients with light brain organic psychosyndrome. Eur Neurol 1986; 25: SI: 115–121.CrossRefGoogle Scholar